Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset - HMS LINCS Database

Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells	Antibodies

|<
<<
Previous
Page 2467 of 3330
Next
>>
>
61651 to 61675 of 83232 records
per page:

Cell	Clinical Subtype	Transcriptional Subtype	Antibody	Perturbagen Concentration	Perturbagen Conc Unit	Biological Replicate ID	Relative Cell Count	Normalized Growth Rate Inhibition Value	Nominal Division Rate
HCC1569	HER2amp	Basal A	Pertuzumab	0.0000032	mg/ml	7447.102	0.9457	0.9333	1.6467
HCC1569	HER2amp	Basal A	Pertuzumab	0.000016	mg/ml	7447.102	0.9905	0.9885	1.6467
HCC1569	HER2amp	Basal A	Pertuzumab	0.00008	mg/ml	7447.102	0.9647	0.9568	1.6467
HCC1569	HER2amp	Basal A	Pertuzumab	0.0004	mg/ml	7447.102	0.9750	0.9695	1.6467
HCC1569	HER2amp	Basal A	Pertuzumab	0.002	mg/ml	7447.102	0.9593	0.9502	1.6467
HCC1569	HER2amp	Basal A	Pertuzumab	0.01	mg/ml	7447.102	0.9470	0.9350	1.6467
HCC1569	HER2amp	Basal A	Pertuzumab	0.05	mg/ml	7447.102	0.9457	0.9333	1.6467
HCC1569	HER2amp	Basal A	Pertuzumab	0.25	mg/ml	7447.102	0.9079	0.8861	1.6467
HCC1569	HER2amp	Basal A	Pertuzumab	1.25	mg/ml	7447.102	0.9179	0.8986	1.6467
MCF 10F	NM	-	Pertuzumab	0.0000032	mg/ml	7487.102	0.9689	0.9590	1.5273
MCF 10F	NM	-	Pertuzumab	0.000016	mg/ml	7487.102	0.9146	0.8864	1.5273
MCF 10F	NM	-	Pertuzumab	0.00008	mg/ml	7487.102	0.9889	0.9854	1.5273
MCF 10F	NM	-	Pertuzumab	0.0004	mg/ml	7487.102	0.9717	0.9628	1.5273
MCF 10F	NM	-	Pertuzumab	0.002	mg/ml	7487.102	0.8741	0.8313	1.5273
MCF 10F	NM	-	Pertuzumab	0.01	mg/ml	7487.102	0.9008	0.8678	1.5273
MCF 10F	NM	-	Pertuzumab	0.05	mg/ml	7487.102	0.9180	0.8911	1.5273
MCF 10F	NM	-	Pertuzumab	0.25	mg/ml	7487.102	0.8097	0.7418	1.5273
MCF 10F	NM	-	Pertuzumab	1.25	mg/ml	7487.102	0.7477	0.6533	1.5273
MCF12A	NM	Basal B	Pertuzumab	0.0000032	mg/ml	7489.102	0.9764	0.9804	2.4234
MCF12A	NM	Basal B	Pertuzumab	0.000016	mg/ml	7489.102	0.9742	0.9785	2.4234
MCF12A	NM	Basal B	Pertuzumab	0.00008	mg/ml	7489.102	0.9575	0.9645	2.4234
MCF12A	NM	Basal B	Pertuzumab	0.0004	mg/ml	7489.102	0.9913	0.9928	2.4234
MCF12A	NM	Basal B	Pertuzumab	0.002	mg/ml	7489.102	0.9273	0.9387	2.4234
MCF12A	NM	Basal B	Pertuzumab	0.01	mg/ml	7489.102	0.9711	0.9760	2.4234
MCF12A	NM	Basal B	Pertuzumab	0.05	mg/ml	7489.102	0.9618	0.9681	2.4234

|<
<<
Previous
Page 2467 of 3330
Next
>>
>
61651 to 61675 of 83232 records
per page:

HMS LINCS Project

Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)